Honasa calls off ₹135 crore acquisition of 58% stake in Fluence Pharma

Mamaearth parent Honasa Consumer has terminated its proposed purchase of a 58% stake in Fluence Pharma after closing conditions were not met. The company said it remains committed to the nutraceuticals category through organic and inorganic opportunities.

— Source publishedWed, 26 Aug, 2026, 10:19 IST·First seen Wed, 26 Aug, 2026, 11:10 IST·Source Inc42 · Buzz

What happened

Honasa Consumer has terminated its proposed ₹135 crore purchase of a 58% Fluence Pharma stake after closing conditions were unmet. Mamaearth’s parent remains

Key facts

  • ₹135 Cr
  • 58% stake
  • 42% stake
  • 5 to 7 years
  • more than 3,000 dermatologists and trichologists
  • ₹16,000 Cr addressable market
  • ₹5,500 Cr FY31 revenue target
  • over 15% FY31 EBITDA margin target
  • offline distribution from about 1.2 lakh to over 3 lakh outlets
  • ₹90.5 Cr Q1 FY27 net profit
  • ₹41.3 Cr year-ago net profit
  • 27% revenue growth
  • ₹755.9 Cr Q1 FY27 operating revenue
  • ₹595.3 Cr year-ago operating revenue
  • ₹481 share price
  • 0.93% share decline

Why this matters

Fluence Pharma’s withdrawal underscores the need for tighter diligence and deal-certainty planning as Honasa continues to seek strategic nutraceuticals entry options.

What to watch

  • Any announcement of a new nutraceutical, supplements, gummies, or ingestible-beauty product from Mamaearth, The Derma Co., Aqualogica, or Dr. Sheth’s.
  • Management commentary on the specific unmet closing conditions, including regulatory, financial, operational, or diligence-related issues.
  • Changes in Honasa’s cash position, acquisition reserve, capital-allocation language, or stated M&A pipeline in quarterly disclosures.
  • New investments, partnerships, or acquisition rumors involving Indian D2C supplements, wellness, women’s health, or dermatology-adjacent brands.
  • Evidence that competitors are bundling topical beauty with ingestible wellness products, increasing pressure on Honasa to establish a category position.
  • Regulatory developments around nutraceutical claims, labeling, FSSAI enforcement, and influencer-led supplement marketing.
  • Launch or pilot ingestible beauty, hair-fall, acne, skin, gut-health, or women’s wellness products under existing Honasa brands.
  • Evaluate targets with established FSSAI compliance, contract manufacturing controls, scientific substantiation, and omnichannel distribution.
  • Seek minority investments, distribution partnerships, or brand licensing arrangements as lower-risk alternatives to a controlling acquisition.
  • Redirect part of the unspent acquisition capital toward offline expansion, brand marketing, product innovation, or working-capital support for core categories.
  • Tighten transaction due diligence and use more condition-based deal structures in future adjacent-category acquisitions.

Also reported by